These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22515923)

  • 1. [Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?].
    Misrai V; Do C; Lhez JM; Elman B; Latorzeff I; Portalez D; Grosclaude P
    Prog Urol; 2012 May; 22(5):273-8. PubMed ID: 22515923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis.
    Mass AY; Agalliu I; Laze J; Lepor H
    J Urol; 2012 Sep; 188(3):786-91. PubMed ID: 22818136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statin use on biochemical outcome following radical prostatectomy.
    Ritch CR; Hruby G; Badani KK; Benson MC; McKiernan JM
    BJU Int; 2011 Oct; 108(8 Pt 2):E211-6. PubMed ID: 21453350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
    Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
    Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients.
    Ku JH; Jeong CW; Park YH; Cho MC; Kwak C; Kim HH
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):63-8. PubMed ID: 20938462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy.
    Rieken M; Kluth LA; Xylinas E; Seitz C; Fajkovic H; Karakiewicz PI; Lotan Y; Briganti A; Loidl W; Faison T; Crivelli JJ; Scherr DS; Bachmann A; Tewari AK; Kautzky-Willer A; Pummer K; Shariat SF
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):367-71. PubMed ID: 23999669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
    Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
    BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.
    Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A
    BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
    Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
    Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.